Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02342353 · ClinicalTrials.gov registry record · Phase 1
Pacritinib in Patients With Endothelial Growth Factor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC) After EGFR Tyrosine Kinase Inhibitor (TKI)
A Phase 1 study, sponsored by Washington University School of Medicine.
- Terminated
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT02342353 is a Phase 1 study that was terminated before completion, run by Washington University School of Medicine. The registered enrollment target is 8 participants.
The verdict
NCT02342353, a Phase 1 study, was terminated before completion, sponsored by Washington University School of Medicine.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
The goal of the study is to find the best dose of pacritinib when given in combination with erlotinib.
Interventions
- DRUG Pacritinib
- DRUG Erlotinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2015-05-18 |
| Est. Completion | 2018-02-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02342353
The ClinicalTrials.gov registry entry for NCT02342353 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pacritinib is the first listed.
NCT02342353 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02342353 about?
NCT02342353 is a clinical study titled "Pacritinib in Patients With Endothelial Growth Factor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC) After EGFR Tyrosine Kinase Inhibitor (TKI)". The goal of the study is to find the best dose of pacritinib when given in combination with erlotinib.
What is the current status of trial NCT02342353?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2015-05-18. Estimated completion is 2018-02-06.
What interventions are being tested in trial NCT02342353?
The interventions under investigation include: Pacritinib (DRUG), Erlotinib (DRUG).
Who is sponsoring clinical trial NCT02342353?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.